In breast cancer, SREBP2 expression is upregulated, and its elevated levels contribute to tumor progression (Ricoult et al., 2016; Huang et al., 2017; Cai et al., 2019; Chen Y. Y. et al., 2022; Hunt et al., 2023). Here, SREBF2 is linked to breast carcinoma.